Not currently recruiting at UCSD
A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease
Crohn DiseaseUstekinumabUstekinumab approximately 6 mg/kg (IV)Ustekinumab 90 mg (SC) Group 1Ustekinumab 90 mg (SC) Group 2
- accepting new patients
- Start Date
- Completion Date
- Janssen-Cilag Ltd.
- To learn how to participate in this trial please click here.
- Phase 3
- Study Type
- Last Updated